Beleggen.nl Markt MonitorMarkt Monitor

Origin Materials

123 Posts
Pagina: «« 1 ... 3 4 5 6 7 | Laatste | Omlaag ↓
  1. forum rang 4 Pitmans 14 maart 2025 07:10
    Leest vooral als "Alles gaat volgens plan"

    Origin Materials, Inc. Reports Operating and Financial Results for Fourth Quarter and Full Year 2024

    Business Wire - Thu, March 13, 2025 at 9:01 PM GMT+1 20 min read

    – On Track for Eight CapFormer Lines in 2025, Ramping to 2026 Revenue Expectation of $110M to $140M –

    – Projecting Run-Rate EBITDA Positive in 2026 –

    – Arranging Debt Financing to Ramp Manufacturing Capacity and Maintain Healthy Cash Floor, No Additional Equity Capital Anticipated –

    WEST SACRAMENTO, Calif., March 13, 2025--(BUSINESS WIRE)--Origin Materials, Inc. ("Origin," "Origin Materials," or the "Company") (Nasdaq: ORGN, ORGNW), a technology company with a mission to enable the world’s transition to sustainable materials, today announced financial results for its fourth quarter and full year ended December 31, 2024.

    "This year was transformational for Origin and Q4 was an inflection point for our caps and closures business," said Origin CEO and Co-Founder John Bissell. "In 2024 we introduced the world to the first fully recyclable 100% PET cap. In Q4, we finished fabrication of our first PET cap manufacturing line and have since turned on commercial production. In February 2025, we announced three new CapFormers are nearing completion, and we expect them to complete factory acceptance testing during Q2. We also confirmed we expect to have eight CapFormer lines online by the end of 2025. Simply put, we are deploying CapFormers as fast as practical to address the substantial and growing customer demand for our products. Our team is now laser focused on Origin’s transformation into a closures manufacturing organization with healthy revenue and margins. In recent weeks, we have made millions of caps, many of which are now in the hands of some of the largest and most famous brands in the world to continue their qualification procedures and although these qualification shipments will not count as sales, they do demonstrate significant and important commercial pull-through. We look forward to naming customers in the weeks or months ahead. Many customers prefer to make an announcement as they draw nearer to having their products with Origin caps on shelves, which we anticipate taking place in Q3 or potentially as soon as late Q2."

    Bissell added: "As we stand up manufacturing, continuous improvement is the rule." Forthcoming lines are expected to incorporate Origin design modifications to increase throughput and result in superior unit economics. To reiterate and expand on our previous guidance: we expect gross margins for caps in the mid double-digits and capital cost per line to end up in the mid-single digit millions. To further improve margins, we may also choose to acquire PET extruders for installations where we believe vertical integration is optimal versus renting extrusion or purchasing sheet from our manufacturing partners. We anticipate the payback period for the average CapFormer line, separate from any extruders, to be less than 18 months. We plan to stand up additional Origin CapFormer lines at a roughly similar pace to our 2025 deployment in 2026, accelerating as capital allows. We also expect full-year 2026 revenue of $110M to $140M, separate from potential licensing revenue."

    Lastly, Origin is updating guidance for expected profitability timing primarily due to a delayed start to line 1 commercial production and the subsequent impact on timing for lines 2 through 8: We now expect to achieve EBITDA positive results on a run-rate basis by the end of 2026, updated from the first half of 2026. Bissell continued: "The fundamentals of our business are strong, including substantial demand for the product, high barriers to entry, and strong strategic interest in Origin across customers and partners. We are increasingly in the enviable position of having indicative demand that significantly exceeds our fulfillment capability for several years to come. Our bigger challenge is to bring supply online as fast as practical to better meet demand and gain market share. We continue to make strides pursuing the opportunity to convert a meaningful amount of market share in the $65B annual caps and closure market to Origin’s PET caps."

    Company Fourth Quarter and Recent Business Highlights

    Origin Materials reported quarterly revenue of $9.2 million generated by the Company’s supply chain activation program. The Company also made significant progress in commercializing its caps and closures business.

    We announced the commencement of PET cap commercial production. We expect our first CapFormer line, in Reed City, Michigan, to produce hundreds of millions of PET caps each year. With the commencement of line 1 production, we anticipate many strategic benefits will be open to us, including more favorable equipment financing terms, more demand for our products, and increased interest in licensing.

    We confirmed that three new CapFormer lines are nearing completion, maintaining our target of having eight lines online by the end of 2025. These new systems will be completed and rolled out on a staggered basis. We have also successfully expanded our CapFormer manufacturing relationships in order to ensure redundancy and additional capacity.

    We are providing more information on timing to revenue realization. Following commencement of commercial production mid-February we have increased our ability to perform customer qualification. We expect to begin realizing caps revenue in earnest concurrently with our next three lines commencing production and customer order fulfillment during Q3, with meaningful revenue generation by Q4 of this year and a strong 2025 exit revenue run-rate. Similarly, we expect the first products with Origin caps to appear on shelves in Q3 2025 or potentially as early as late Q2 2025.

    We are in the process of securing debt financing to fund our capital equipment build-out and working capital needs to maintain a healthy minimum cash floor at all times. The expected short payback period per line makes for an attractive financing opportunity for lenders, and we are curating a number of financing proposals for all lines we have on order and in production. We do not anticipate needing to raise equity capital to finance our growth.

    We significantly enhanced our IP portfolio, deepening Origin’s technology advantage. Our patent portfolio now comprises over 70 issued patents, as well as dozens of pending applications. In January 2025, five applications published covering single and double-walled closures, knurled and threaded closures, and methods of making our closures via thermoforming. Origin’s IP lets us make a new, lighter, better-performing cap than our competitors can make, using a proprietary CapForming method our competitors can't duplicate.
  2. forum rang 4 Pitmans 14 maart 2025 07:11
    Results for Fourth Quarter and Full Year 2024

    Cash, cash equivalents and marketable securities were $102.9 million as of December 31, 2024.

    Revenue for the fourth quarter was $9.2 million compared to $13.1 million in the prior-year period, generated by the Company’s supply chain activation program.

    Revenue for the full year was $31.3 million compared to $28.8 million in the prior-year period, generated mainly by the Company’s supply chain activation program.

    Operating expenses for the fourth quarter were $16.2 million compared to $19.8 million in the prior-year period, a decrease of $3.6 million consisting primarily of a $2.7 million decrease in research and development expenses and a $1.3 million decrease in general and administrative expenses.

    Full year 2024 operating expenses were $85.3 million compared to $60.1 million in the prior-year period, an increase of $25.2 million driven primarily by $15.2 million in non-cash impairment charges, a $5.4 million increase in general and administrative expenses, a $7.4 million increase in depreciation expenses driven by Origin 1 coming online during the fourth quarter of 2023, partially offset by a $2.8 million decrease in research and development expenses. A significant portion of costs incurred during the year of 2023 were capitalized as part of the development of Origin 1, whereas the costs to operate and maintain the plant are included in general and administrative expenses in 2024.

    Net loss was $13.5 million for the fourth quarter compared to $10.4 million in the prior-year period. Full year 2024 net loss was $83.7 million compared to net income of $23.8 million in the prior-year period, a decrease of $107.5 million driven primarily by $25.2 million increase in total operating expenses, a $32.8 million decrease in fair value of common stock warrants liability, and a $41.7 million decrease in fair value of earnout liability.

    Adjusted EBITDA loss was $11.1 million for the fourth quarter compared to $11.0 million in the prior-year period. Full year 2024 Adjusted EBITDA loss was $48.4 million compared to $41.6 million in the prior-year period.

    Shares outstanding as of December 31, 2024 were 148.6 million including 3.0 million shares that are subject to forfeiture based on share price performance targets previously disclosed in our filings.

    For a reconciliation of non-GAAP figures to the applicable GAAP figures, please see the table captioned ‘Reconciliation of GAAP and Non-GAAP Results' set forth at the end of this press release.

    Webcast and Conference Call Information

    Company management will host a webcast and conference call on March 13, 2025, at 5:00 p.m. Eastern Time, to discuss the Company's financial results.

    Interested investors and other parties can listen to a webcast of the live conference call and access the Company’s quarterly update presentation by logging onto the Investor Relations section of the Company's website at investors.originmaterials.com/.

    The conference call can be accessed live over the phone by dialing +1-844-481-2515 (domestic) or +1-412-317-0644 (international). A telephonic replay will be available approximately three hours after the call by dialing 1-844-512-2921, or for international callers, +1-412-317-6671. The conference ID for the live call and pin number for the replay is 10197107. The replay will be available until 11:59 p.m. Eastern Time on March 20, 2025.
  3. forum rang 4 Pitmans 14 maart 2025 07:19
    Eerste marktreactie : in de laatste minuten reguliere handel zo'n 5% stijging, nabeurs nog eens 5% erbij. Dit alles wel na een daling met het sentiment van de laatste dagen mee naar een miezerige $0.81 , slot nabeurs $ 0.95
123 Posts
Pagina: «« 1 ... 3 4 5 6 7 | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beleggen.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.102
AB InBev 2 5.529
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.949
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.807
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.782
Aedifica 3 925
Aegon 3.258 323.007
AFC Ajax 538 7.088
Affimed NV 2 6.301
ageas 5.844 109.897
Agfa-Gevaert 14 2.062
Ahold 3.538 74.345
Air France - KLM 1.025 35.249
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.048
Alfen 16 25.103
Allfunds Group 4 1.514
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 409
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.629
AMG 971 134.099
AMS 3 73
Amsterdam Commodities 305 6.740
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.031
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.789
Arcelor Mittal 2.034 320.895
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.342
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.564
ASML 1.766 109.548
ASR Nederland 21 4.505
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.733
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.438